Cargando…
Evidences for the Anti-panic Actions of Cannabidiol
BACKGROUND: Panic disorder (PD) is a disabling psychiatry condition that affects approximately 5% of the worldwide population. Currently, long-term selective serotonin reuptake inhibitors (SSRIs) are the first-line treatment for PD; however, the common side-effect profiles and drug interactions may...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412699/ https://www.ncbi.nlm.nih.gov/pubmed/27157263 http://dx.doi.org/10.2174/1570159X14666160509123955 |
_version_ | 1783233060185047040 |
---|---|
author | Soares, Vanessa P. Campos, Alline C. |
author_facet | Soares, Vanessa P. Campos, Alline C. |
author_sort | Soares, Vanessa P. |
collection | PubMed |
description | BACKGROUND: Panic disorder (PD) is a disabling psychiatry condition that affects approximately 5% of the worldwide population. Currently, long-term selective serotonin reuptake inhibitors (SSRIs) are the first-line treatment for PD; however, the common side-effect profiles and drug interactions may provoke patients to abandon the treatment, leading to PD symptoms relapse. Cannabidiol (CBD) is the major non-psychotomimetic constituent of the Cannabis sativa plant with anti-anxiety properties that has been suggested as an alternative for treating anxiety disorders. The aim of the present review was to discuss the effects and mechanisms involved in the putative anti-panic effects of CBD. METHODS: electronic database was used as source of the studies selected selected based on the studies found by crossing the following keywords: cannabidiol and panic disorder; canabidiol and anxiety, cannabidiol and 5-HT1A receptor). RESULTS: In the present review, we included both experimental laboratory animal and human studies that have investigated the putative anti-panic properties of CBD. Taken together, the studies assessed clearly suggest an anxiolytic-like effect of CBD in both animal models and healthy volunteers. CONCLUSION: CBD seems to be a promising drug for the treatment of PD. However, novel clinical trials involving patients with the PD diagnosis are clearly needed to clarify the specific mechanism of action of CBD and the safe and ideal therapeutic doses of this compound. |
format | Online Article Text |
id | pubmed-5412699 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Bentham Science Publishers |
record_format | MEDLINE/PubMed |
spelling | pubmed-54126992017-08-01 Evidences for the Anti-panic Actions of Cannabidiol Soares, Vanessa P. Campos, Alline C. Curr Neuropharmacol Article BACKGROUND: Panic disorder (PD) is a disabling psychiatry condition that affects approximately 5% of the worldwide population. Currently, long-term selective serotonin reuptake inhibitors (SSRIs) are the first-line treatment for PD; however, the common side-effect profiles and drug interactions may provoke patients to abandon the treatment, leading to PD symptoms relapse. Cannabidiol (CBD) is the major non-psychotomimetic constituent of the Cannabis sativa plant with anti-anxiety properties that has been suggested as an alternative for treating anxiety disorders. The aim of the present review was to discuss the effects and mechanisms involved in the putative anti-panic effects of CBD. METHODS: electronic database was used as source of the studies selected selected based on the studies found by crossing the following keywords: cannabidiol and panic disorder; canabidiol and anxiety, cannabidiol and 5-HT1A receptor). RESULTS: In the present review, we included both experimental laboratory animal and human studies that have investigated the putative anti-panic properties of CBD. Taken together, the studies assessed clearly suggest an anxiolytic-like effect of CBD in both animal models and healthy volunteers. CONCLUSION: CBD seems to be a promising drug for the treatment of PD. However, novel clinical trials involving patients with the PD diagnosis are clearly needed to clarify the specific mechanism of action of CBD and the safe and ideal therapeutic doses of this compound. Bentham Science Publishers 2017-02 2017-02 /pmc/articles/PMC5412699/ /pubmed/27157263 http://dx.doi.org/10.2174/1570159X14666160509123955 Text en © 2017 Bentham Science Publishers https://creativecommons.org/licenses/by-nc/4.0/legalcode This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/legalcode), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited. |
spellingShingle | Article Soares, Vanessa P. Campos, Alline C. Evidences for the Anti-panic Actions of Cannabidiol |
title | Evidences for the Anti-panic Actions of Cannabidiol |
title_full | Evidences for the Anti-panic Actions of Cannabidiol |
title_fullStr | Evidences for the Anti-panic Actions of Cannabidiol |
title_full_unstemmed | Evidences for the Anti-panic Actions of Cannabidiol |
title_short | Evidences for the Anti-panic Actions of Cannabidiol |
title_sort | evidences for the anti-panic actions of cannabidiol |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412699/ https://www.ncbi.nlm.nih.gov/pubmed/27157263 http://dx.doi.org/10.2174/1570159X14666160509123955 |
work_keys_str_mv | AT soaresvanessap evidencesfortheantipanicactionsofcannabidiol AT camposallinec evidencesfortheantipanicactionsofcannabidiol |